[Early conversion from XXXX to sirolimusto after renal transplantation:a prospective, open-label and non-randomized control study].

@entity1 @entity644 @entity6 @entity9909 @entity3446 @entity1371 @entity1011 @entity230 @entity6051 @entity413
OBJECTIVE: To explore the efficacy and safety of designed early conversion from @entity9909 (CNI) to @entity3446 (SRL) as major immunosuppressive therapy in renal transplant recipients with stable renal function. METHODS: A prospective, open-label and non-randomized control study was performed for 112 renal transplant recipients (3-6 months post-operation) with stable renal function between June 2008 and June 2011. The @entity1 in SRL group (n = 57) switched to @entity3446 while those in CNI group (n = 55) continued CNI. The dosing of @entity6051 mofetil and @entity230 had no change. They were followed up for at least 24 months to evaluate the acute rejection, @entity1 and graft survival, renal function, estimated glomerular filtration rate (eGFR), blood lipids, blood @entity413 , liver function and urinary protein at 1, 6, 12 and 24 months after inclusion. Adverse events were also recorded. RESULTS: The serum @entity1011 of SRL group decreased significantly after conversion ( (89.2    24.7), (87.6    23.8), (86.1    20.4), (86.7    19.7) vs (117.0    16.3)   mol/L, all P < 0.05). CNI group showed no improvement of renal function.SRL group had a significantly higher eGFR than CNI group (P < 0.05). Among 3 cases of acute rejection, there were 2 in SRL group and 1 in CNI group (P > 0.05). Blood lipids in SRL group increased significantly at 1 month after conversion (P < 0.05) and reverted back to average level after intervention (P > 0.05).SRL group had a drop of hemoglobin level within the normal range. Two @entity1 in SRL group developed @entity1371 and another 2 @entity1 had oral ulcer. They all improved after treatment. During follow-ups, 1 case of mild @entity644 was found in SIR group. Three @entity1 were diagnosed with @entity6 (1 in SRL group vs 2 in CNI group). CONCLUSIONS: Early conversion from CNI to SRL as major immunosuppressive therapy in renal transplant recipients with stable renal function further improves renal function. There is no higher rate of acute rejection during follow-up.Elevated blood lipids after conversion may be easily controlled. No other adverse events are found.
